REQUEST A REP

PHARMACOKINETIC INFORMATION

ARISTADA provides consistent and sustained medication levels throughout the dosing period1

MEDIAN SIMULATED ARIPIPRAZOLE PLASMA CONCENTRATIONS FOR THE ARISTADA INITIO REGIMENa AND ARISTADA 2-MONTH DOSE (1064 MG)2

Modeling-based simulations of ARISTADA INITIO™ (aripiprazole lauroxil) regimen and ARISTADA® (aripiprazole lauroxil) 1064 mg q8wks yielded aripiprazole concentrations that fall within the estimated aripiprazole exposure range of the studied approved dose regimens of 441 mg q4wks and 882 mg q4wks.2

aThe ARISTADA INITIO regimen is defined as a single injection of ARISTADA INITIO (675 mg) given in conjunction with a single 30-mg dose of oral aripiprazole.3

  • With the addition of a single intramuscular injection of ARISTADA INITIO and 30 mg of oral aripiprazole at the time of the first ARISTADA dose, aripiprazole concentrations reach relevant levels within 4 days3

See the proprietary LinkeRx® technology behind ARISTADA INITIO and ARISTADA

Watch Video
References: 1. Hard ML, Wehr AY, Sadler BM, Mills RJ, von Moltke L. Population pharmacokinetic analysis and model-based simulations of aripiprazole for a 1-day initiation regimen for the long-acting antipsychotic aripiprazole lauroxil [published online ahead of print June 11, 2018]. Eur J Drug Metab Pharmacokinet. doi:10.1007/s13318-018-0488-4. 2. Data on file. Alkermes, Inc. 3. ARISTADA INITIO [package insert]. Waltham, MA: Alkermes, Inc; 2018.